Detalles de la búsqueda
1.
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.
Liver Int
; 41(6): 1227-1242, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33590598
2.
Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
BMC Infect Dis
; 19(1): 134, 2019 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30744563
3.
Cost Consequence Analysis of the Management of Hyperkalemia by Patiromer and Optimization of Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Chronic Kidney Disease Patients in Saudi Arabia.
Saudi J Kidney Dis Transpl
; 33(Supplement): S39-S52, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37102523
4.
Ward based goal directed fluid therapy (GDFT) in acute pancreatitis (GAP) trial: A feasibility randomised controlled trial.
Int J Surg
; 104: 106737, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35835346
5.
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018.
Eur J Health Econ
; 22(4): 505-518, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33751289
6.
The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.
J Med Econ
; 23(1): 86-97, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31262225
7.
Authors' reply to Tavabie.
BMJ
; 355: i5436, 2016 10 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27729355
8.
Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance.
BMJ
; 354: i4428, 2016 Sep 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27605111
Resultados
1 -
8
de 8
1
Próxima >
>>